| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Low melting point agarose does not have a biological target as it is a gel matrix material rather than a pharmacologically active compound. Its function is physicochemical—it forms a porous gel matrix that separates biomolecules based on size during electrophoresis. The low melting point allows for the recovery of DNA or RNA fragments from the gel by melting at moderate temperatures without damaging the nucleic acids. The agarose gel matrix does not interact specifically with biological molecules but provides a sieving medium for their separation.
|
|---|---|
| ln Vitro |
Low melting point agarose is a biochemical reagent that can be utilized in life science research as an organic substance or biological material.
In vitro, low melting point agarose exhibits no pharmacological activity as it is a gel matrix material. Its utility is demonstrated in molecular biology applications for DNA and RNA electrophoresis, particularly for the recovery of nucleic acid fragments from gels. The gel allows the separation of nucleic acids by size, and the low melting point enables easy recovery of DNA or RNA bands by melting the gel at 65-70°C. The compound is also used in cell culture for cell encapsulation and tissue engineering applications. |
| ln Vivo |
Low melting point agarose is not a pharmacologically active agent and does not exhibit in vivo therapeutic activity. It is used as a biochemical reagent for molecular biology research and as a biomaterial for cell encapsulation and tissue engineering applications. The compound is not intended for human or animal exposure as a therapeutic agent. It is used in research laboratories for gel electrophoresis and related applications. No therapeutic efficacy has been reported for this compound.
|
| Enzyme Assay |
In vitro assays for low melting point agarose focus on its gel properties rather than receptor binding. A standard protocol involves preparing a gel by dissolving the agarose in electrophoresis buffer (typically TAE or TBE) at concentrations of 1-2%, heating to dissolve, and pouring into a gel casting tray. After solidification, DNA or RNA samples are loaded and electrophoresed at 4-10 V/cm. For DNA recovery, the desired band is excised from the gel and melted at 65-70°C for DNA extraction using spin columns or phenol-chloroform extraction. Quality control includes gel strength, gelling temperature, and melting temperature measurements.
|
| Cell Assay |
In vitro cell culture experiments with low melting point agarose typically involve cell encapsulation or 3D culture applications. Cells are suspended in a warm agarose solution (typically 0.5-2% in culture medium) at 37-40°C and allowed to gel at room temperature. The agarose provides a 3D matrix for cell growth and can be used to study cell behavior in a scaffold environment. Cell viability is assessed using Live/Dead staining or MTT assays. The agarose itself is biologically inert and does not support cell adhesion without modification.
|
| Animal Protocol |
In vivo animal studies with low melting point agarose are limited to biocompatibility studies for tissue engineering applications. A standard protocol involves implanting agarose hydrogels (with or without encapsulated cells) subcutaneously or at specific tissue sites in rodents. Animals are monitored for signs of inflammation or rejection over periods ranging from days to weeks. At study termination, the implantation sites are excised and examined histologically for tissue reaction, capsule formation, and inflammatory cell infiltration. The agarose is not used in efficacy studies as it is not a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of low melting point agarose are not applicable as it is a non-absorbable polymer. Agarose is not absorbed from the gastrointestinal tract and is not metabolized. When used as an implant, the material is biostable and remains at the implantation site with minimal degradation. The polymer is eventually cleared through normal tissue remodeling processes. No systemic absorption or distribution occurs.
|
| Toxicity/Toxicokinetics |
Low melting point agarose is generally considered biocompatible and non-toxic for research applications. The material is not classified as a carcinogen, mutagen, or reproductive toxicant. Standard laboratory precautions should be followed when handling the compound, including the use of gloves and safety glasses. The compound should be stored at room temperature in a dry place. No acute toxicity data are available for systemic exposure.
|
| Additional Infomation |
Agarose is a linear polysaccharide composed of alternating D-galactose and 3,6-anhydro-α-L-galactopyranose residues linked by α-(1→3)- and β-(1→4)-glycosidic bonds. It is a marine metabolite functionally related to galactans. Agarose has been reported in Gracilaria dura, and relevant data are available.
Low melting point agarose is a polysaccharide polymer used as a gel matrix for DNA and RNA electrophoresis, particularly for the recovery of nucleic acid fragments from gels. It is also used in cell encapsulation and tissue engineering applications. The low melting point (65-70°C) allows for the recovery of DNA or RNA from gels without damaging the nucleic acids. The compound has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is physicochemical—forming a gel matrix for size-based separation of biomolecules. |
| Molecular Formula |
C10H15N3O3
|
|---|---|
| Molecular Weight |
225.2474
|
| Exact Mass |
630.2
|
| CAS # |
9012-36-6
|
| PubChem CID |
11966311
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
993.9±65.0 °C at 760 mmHg
|
| Melting Point |
≤90 °C (4% in water)(lit.)
|
| Flash Point |
554.9±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.679
|
| LogP |
-2.85
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
43
|
| Complexity |
946
|
| Defined Atom Stereocenter Count |
20
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4395 mL | 22.1976 mL | 44.3951 mL | |
| 5 mM | 0.8879 mL | 4.4395 mL | 8.8790 mL | |
| 10 mM | 0.4440 mL | 2.2198 mL | 4.4395 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
